首页> 外文期刊>Diabetes care >Abnormal LDIflare but normal quantitative sensory testing and dermal nerve fiber density in patients with painful diabetic neuropathy.
【24h】

Abnormal LDIflare but normal quantitative sensory testing and dermal nerve fiber density in patients with painful diabetic neuropathy.

机译:患有糖尿病性神经病变的患者的LDIflare异常,但定量感觉测试和皮肤神经纤维密度正常。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: Abnormal small nerve fiber function may be an early feature of diabetic neuropathy and may also underlie painful symptoms. Methods for assessing small-fiber damage include quantitative sensory testing (QST) and determining intraepidermal nerve fiber density. We recently described a reproducible physiological technique, the LDIflare, which assesses small-fiber function and thus may reflect early dysfunction before structural damage. The value of this technique in painful neuropathy was assessed by comparing it with QST and dermal nerve fiber density (NFD). RESEARCH DESIGN AND METHODS: Fifteen healthy control subjects, 10 subjects with type 2 diabetes and painful neuropathy (PFN), and 12 subjects with type 2 diabetes and painless neuropathy (PLN) were studied. LDIflare and QST were performed on the dorsum of the foot, and dermal NFD was determined. RESULTS: Results of both large- and small-fiber quantitative sensory tests were abnormal in patients with PLN but not those with PFN compared with control subjects. Dermal NFD was also significantly reduced in the PLN group compared with control subjects (205.8 +/- 165.3 vs. 424.9 +/- 176.3 [mean +/- SD]; P = 0.003) but not in the PFN group (307.6 +/- 164.5). In contrast, the LDIflare (square centimeters) was reduced in both PFN (1.59 +/- 0.41) and PLN (1.51 +/- 0.56) groups compared with control subjects (4.38 +/- 1.4) (P < 0.001 for both). NFD correlated significantly with the LDIflare (r = 0.57, P < 0.0001). CONCLUSIONS: The LDIflare demonstrated impaired small-fiber function in patients with PFN when other assessments revealed no abnormality. We believe that this method has potential diagnostic value, particularly because it is noninvasive, has excellent reproducibility, and correlates with NFD. Furthermore, it may have an important role in assessing preventative therapies in early neuropathy.
机译:目的:小神经纤维功能异常可能是糖尿病性神经病的早期特征,也可能是疼痛症状的基础。评估小纤维损伤的方法包括定量感觉测试(QST)和确定表皮内神经纤维密度。我们最近描述了一种可重现的生理技术LDIflare,该技术可评估小纤维的功能,因此可能反映出结构破坏之前的早期功能障碍。通过将该技术与QST和皮肤神经纤维密度(NFD)进行比较,评估了该技术在疼痛性神经病变中的价值。研究设计与方法:研究对象为15名健康对照者,10名2型糖尿病和无痛性神经病(PFN)受试者和12名2型糖尿病和无痛性神经病(PLN)。对足背进行LDIflare和QST,并测定真皮NFD。结果:与对照组相比,PLN患者的大纤维和小纤维定量感觉测试结果均异常,而PFN患者则没有。与对照组相比,PLN组的皮肤NFD也显着降低(205.8 +/- 165.3与424.9 +/- 176.3 [平均值+/- SD]; P = 0.003),而PFN组则没有(307.6 +/- 164.5)。相比之下,与对照组(4.38 +/- 1.4)相比,PFN(1.59 +/- 0.41)和PLN(1.51 +/- 0.56)组的LDIflare(平方厘米)均降低(两者均P <0.001)。 NFD与LDIflare显着相关(r = 0.57,P <0.0001)。结论:当其他评估未发现异常时,LDIflare证明PFN患者小纤维功能受损。我们认为该方法具有潜在的诊断价值,尤其是因为它是非侵入性的,具有出色的可重复性,并且与NFD相关。此外,它可能在评估早期神经病的预防性治疗中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号